Evidence map›Paper›PMID 40909503›Full record

ArticlebioRxiv : the preprint server for biology2025

Neuraminidase-on-a-string nanoparticles probe how antigenic distance shapes elicited humoral immunity.

Rochel Hecht, Faez Amokrane Nait Mohamed, Daniel Lingwood, Aaron G Schmidt

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rochel HechtRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, 02139, USA.
Faez Amokrane Nait MohamedRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, 02139, USA.
Daniel LingwoodRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, 02139, USA.ORCID 0000-0001-5631-9238
Aaron G SchmidtRagon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, 02139, USA.ORCID 0000-0003-3627-2553

Funding

Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component A: Vaccine Center75N93019C00050 · NIAID · DUKE UNIVERSITY · PI MOODY, TONY · 2019 to 2025
$69.1M
Virology CoreP01AI089618 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI STEPHEN COPLAN HARRISON · 2011 to 2026
$40.0M
MOLECULAR BIOPHYSICS TRAINING GRANTT32GM008313 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MURTHY, VENKATESH N · 1989 to 2023
$14.6M
Innate-like BCR activity as a template for universal vaccination against influenza virusR01AI137057 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHACKERIAN, BRYCE C, LINGWOOD, DANIEL · 2018 to 2022
$2.6M
Triggering germline-encoded broadly neutralizing antibody responses against influenza virusR01AI153098 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BATISTA, FACUNDO DAMIAN, LINGWOOD, DANIEL · 2020 to 2023
$2.1M
Systemic coordination of pro-inflammatory immune reactions through dendritic cell-restricted sIL6R biogenesisR01AI155447 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2021 to 2025
$2.0M
Sex differences in a cytokine controlling antibody class switch recombinationR21AI193280 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2025 to 2025
$439k
Structure-based design of neuraminidase immunogens for next-generation influenza vaccinesF30AI181355 · NIAID · HARVARD MEDICAL SCHOOL · PI HECHT, ROCHEL · 2024 to 2025
$96k
NIAID NIH HHS 75N93019C00050NIAID NIH HHS F30 AI181355NIAID NIH HHS P01 AI089618NIAID NIH HHS R01 AI137057NIAID NIH HHS R01 AI153098NIAID NIH HHS R01 AI155447NIAID NIH HHS R21 AI193280NIGMS NIH HHS T32 GM008313
6 · The paper itself

Abstract

Understanding how antigenic distance influences cross-reactive responses can inform vaccine design. Multivalent displays of viral proteins can improve B cell activation due to receptor cross-linking, and mosaic nanoparticles that incorporate variants can lead to cross-reactive B cell responses recognizing conserved epitopes. Here, we used the influenza virus neuraminidase to develop a neuraminidase-on-a-string platform displaying neuraminidase dimer pairs conjugated to a nanocarrier To systematically assess the influence of antigenic distance on humoral immunity, we paired H2N2 neuraminidase with either divergent H3N2 or H11N9 neuraminidases. We found that nanoparticle immunizations with heterologous antigens elicited sera with greater breadth and enhanced enzymatic inhibition relative to immunizations that incorporated a single neuraminidase strain. While sera reactivity for H2N2 neuraminidase was not impacted by inclusion of a second strain, strain-specific responses correlatively increased with the antigenic distance between neuraminidase components. These data show how neuraminidase strain selection for multivalent display immunizations influences elicited breadth and cross-reactivity, highlighting findings that may extend to other viral antigens.

Indexed as

antigenic distancebreadthnanoparticle immunogensneuraminidasenext-generation vaccinesprotein engineering

Identifiers

PMID40909503
PMCPMC12407795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.